학술논문
Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegenerʼs) or Microscopic Polyangiitis
Document Type
Academic Journal
Author
Puéchal, Xavier; Pagnoux, Christian; Perrodeau, Élodie; Hamidou, Mohamed; Boffa, Jean-Jacques; Kyndt, Xavier; Lifermann, François; Papo, Thomas; Merrien, Dominique; Smail, Amar; Delaval, Philippe; Hanrotel-Saliou, Catherine; Imbert, Bernard; Khouatra, Chahéra; Lambert, Marc; Leské, Charles; Ly, Kim H.; Pertuiset, Edouard; Roblot, Pascal; Ruivard, Marc; Subra, Jean-François; Viallard, Jean-François; Terrier, Benjamin; Cohen, Pascal; Mouthon, Luc; Le Jeunne, Claire; Ravaud, Philippe; Guillevin, Loïc; Rispal, P.; Baidi, N.; Chrétien, O.; Cevallos, R.; Ducroix, J.-P.; Darmaillacq, J.-G.; Dubas, F.; Maghakian, M.-N.; Moreau, C.; Dubos-Arvis, C.; Frognier, R.; Gobert, P.; Pollini, J.; Pingat, D.; Janin-Manificat, L.; Lafon, B.; Kettaneh, A.; Moiton, M.; Ragnaud, J. M.; Boudray, C.; Raphanel, B.; Renand, J.-P.; Roux, M.; Bonnaire, G.; Guiso, A.; André, J. M.; Perrichot, R.; Louvet, J.; Artigues, N.; Bienvenu, B.; de Ligny, Hurault B.; Le Hello, C.; Letellier, P.; Lobbedez, T.; Ollivier, Y.; Pujo, M.; Ryckelynck, J.-P.; Montseny, J.-J.; Collet, P.; Ayach, B.; Dion, J.-J.; Mouawad, H.; Damade, R.; Dupouët, L.; Asgaraly, K.; Depernet, B.; Colin, T.; Ioos, V.; Rieu, V.; Belmatoug, N.; Foulon, L.; Jebrak, G.; du Coedic, L.; Bachmeyer, C.; Dumoulin, A.; Godeau, B.; Khellaf, M.; Michel, M.; Pastural, M.; Schaeffer, A.; Geffroy, M.; Bielefeld, P.; Fichet, D.; Saraux, J.-L.; Vinzio, S.; Ehrlacher, P.; Azria, A.; Mariette, X.; Tiab, M.; Delansorne, D.; Boullanger, N.; Closs-Prophette, F.; Goldstein, A.; Bouscaud, L.; Meunier, V.; Hachulla, E.; Hatron, P.-Y.; Launay, D.; Hottelart, C.; Liozon, E.; Longuet, O.; Loustaud-Ratti, V.; Soria, P.; Vidal, E.; Geffray, L.; Henri, P.; Landru, I.; Guillemot, J.-M.; Le Noach, J.; Cordier, J.-F.; Cottin, V.; Gentil, B.; Demolombe-Rague, S.; Girard-Madoux, M.-H.; Ninet, J.; Pinède, L.; Meynieux, J.-P.; Serratrice, J.; Xeridat, B.; Bagnères, D.; Roudier, J.; Denis, B.; Boillet, N.; Geraads, A.; Teyssandier, R.; Degraeve, F.; Le Quellec, A.; Rivière, S.; Rogé, C.; Fauchay, J.-P.; Wahl, D.; Agard, C.; Généreau, T.; Meker, D.; Bensakel, S.; Vecina, F.; Aubier, M.; Foulon, G.; Lelièvre, P.; Lidove, O.; Mignon, F.; Meyer, O.; Piperaud, M.; Queffeulou, G.; Vrtovsnik, F.; Aouba, A.; Arène, J.-P.; Bérezné, A.; Le Guern, V.; Amoura, Z.; Benveniste, O.; Dimitri, D.; Huong, Lê Thi D.; Bergeron, A.; Bourgarit, A.; Farge, D.; Mahr, A.; Martinez, F.; Séréni, D.; Aslangul, E.; Arnal, C.; Cadranel, J.; Daugas, E.; Pelle, G.; Rossert, J.; Wislez, M.; Gayraud, M.; Bruet, A.; Hillion, Y.; Paccalin, M.; Léone, J.; Pennaforte, J.-L.; Barbier, S.; Legallicier, B.; Dominique, S.; Charasse, C.; Coëtmeur, D.; Duhamel, E.; Goulias, J.-P.; Bournerias, F.; Gautherie, P.; Schlienger, J.-L.; Vidal, A.; Diot, E.; Diot, P.; Vanhille, P.; Bindi, P.; Cervantes, G.
Source
Arthritis & Rheumatology. Mar 01, 2016 68(3):690-701
Subject
Language
English
ISSN
2326-5191
Abstract
OBJECTIVE.: METHODS.: RESULTS.: Data from 10 years of followup were available for 112 (88.8%) of the 126 original trial participants. The median followup time was 11.9 years (95% confidence interval [95% CI] 11.3–12.5 years). In patients receiving AZA and those receiving MTX, the 10-year overall survival rates were 75.1% (95% CI 64.8–86.9%) and 79.9% (95% CI 70.3–90.8%) (P = 0.56), respectively, and relapse-free survival rates were 26.3% (95% CI 17.3–40.1%) and 33.5% (95% CI 23.5–47.7%) (P = 0.29), respectively. No between-treatment differences were observed with regard to rates of relapse, adverse events, damage, survival without severe side effects, and survival without relapse and severe side effects. In analyses limited to the 97 patients with GPA, no between-treatment differences in survival rates were observed. The 10-year relapse-free survival rate was lower in patients with GPA than in patients with MPA. However, in the multivariate analysis, anti–proteinase 3 antineutrophil cytoplasmic antibody (ANCA) positivity, and not GPA, was retained as being independently associated with the relapse rate. CONCLUSION.